CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

11 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

07 Nov 2023 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

19 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

10 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces $23 Million Registered Direct Offering

29 Sep 2023 06:35:51 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

29 Sep 2023 06:30:58 By Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

02 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

13 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

30 Jun 2023 08:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

13 Jun 2023 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

07 Jun 2023 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 15:01:01 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

04 May 2023 08:00:01 By Nasdaq GlobeNewswire

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

27 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

23 Mar 2023 08:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

08 Mar 2023 08:00:00 By Nasdaq GlobeNewswire